431 results on '"Pawarode, Attaphol"'
Search Results
102. An Early Biomarker Algorithm Predicts Lethal Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation
103. Rational Modification of Human Gut Microbiome and Metabolites By Dietary Resistant Starch in Allogeneic Hematopoietic Stem Cell Transplantation: A Feasibility Study
104. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation
105. Phase 1 Study of Carfilzomib in Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
106. Alpha 1 Anti-Trypsin (AAT): Novel Strategy to Treat Steroid Refractory Acute Graft Versus Host Disease
107. Quantitative Analysis of MR Imaging to Assess Treatment Response for Patients with Multiple Myeloma by Using Dynamic Intensity Entropy Transformation: A Preliminary Study
108. Phase 1 Study of Carfilzomib for the Prevention of Relapse and Graft-Versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
109. 92 - Impact of Broncho-Alveolar Lavage on the Diagnosis and Management of Pulmonary Complications Following Hematopoietic Cell Transplantation
110. 100 - Ultrasensitive Detection of Genomic Minimal Residual Disease before or after Allogeneic Hematopoietic Cell Transplantation for Adult AML is Associated with Inferior Survival
111. 91 - Correlation of Radiographic Abnormalities on Computer Tomography (CT) with Broncho-Alveolar Lavage (BAL) Results. What are Our Radiologists Reading?
112. Phase 2 Study of Pembrolizumab during Lymphodepleted State after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Patients
113. Phase II Clinical Trial of Etanercept Plus Extracorporeal Photopheresis GVHD Prophylaxis Following Unrelated Donor Reduced Intensity Transplant
114. The Graft-Versus-Lymphoma Effect in Diffuse Large B-Cell Lymphoma
115. Prognostic Value of TGFβ at Diagnosis of Chronic GvHD
116. Routine Prophylaxis of Pneumocystis Jirovecii Pneumonia in Recipients of Autologous Hematopoietic Stem Cell Transplantation
117. Double Umbilical Cord Blood Transplantation after Novel Myeloablative Conditioning Using FluBu4/TLI
118. The Impact of Mold Infections after Allogeneic Transplantation
119. Allogeneic Hematopoietic Cell Transplant (Allo-HCT) for Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma: The University of Michigan Experience
120. Pneumocystis Jirovecii Pneumonia In Recipients Of Autologous Hematopoietic Stem Cell Transplantation: A 10-Year Cohort Study
121. Application Of BOS 0-Potential Criteria As a Predictor For Bronchiolitis Obliterans Syndrome In Allogeneic Stem Cell Transplant Patients
122. A Prospective Study of Allogeneic Transplant for Older Patients with Acute Myelogenous Leukemia (AML) Indicates that Unrelated Donor Transplants are as Efficacious as Related Donor, with Favorable Outcomes for Intermediate Risk Disease
123. The Use of Early Spirometric Changes and IGF-1 Levels for the Detection of Patients at Risk for BOS
124. A Combination of Clinical Characteristics and Day 7 Biomarker Concentrations Predicts Graft-Versus-Host Disease Following Hematopoietic Cell Transplantation From Related Donors
125. Phase 2 Study of Allogeneic Hematopoietic Cell Transplant (HCT) Following Intermediate-Intensity Fludarabine and Busulfan x 4 (FluBu4) Conditioning for High-Risk or Advanced Multiple Myeloma
126. Biomarkers of Extracellular Matrix Remodeling in Chronic GVHD
127. Impact of Dose Intensification of FluBu2 to FluBu4 on Transplant Related Mortality, Relapse, and Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia in Remission
128. Unrelated Donor Transplants for Older AML Patients Using a Low Dose TBI Containing Regimen Are As Efficacious As Related Donor Transplants, and Exhibit Favorable Outcomes for Intermediate Risk Disease.
129. Targeting Histone Deacetylases As a New Strategy for Graft Versus Host Disease Prevention
130. An Algorithm Combining Clinical Characteristics and Day 7 Biomarker Concentrations Predicts Future Graft-Versus-Host Disease Following Related Donor Hematopoietic Cell Transplantation
131. Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies
132. Three Biomarker Panel at Day 7 and 14 Can Predict Development of Grade II-IV Acute Graft-Versus-Host Disease
133. Allogeneic Hematopoietic Stem Cell Transplantation with Clofarabine/Busulfan × 4 (CloBu4) Conditioning Exhibits Significant Anti-Tumor Activity In Non - Remission Hematologic Malignancies, Especially In AML
134. Long-term safety and efficacy of cyclosporin A therapy for T-cell large granular lymphocyte leukemia
135. Standard Gvhd Prophylaxis Augmented with TNF-Inhibition in Alternative Donor HCT: Lower TNFR1 Levels Correlate with Better Outcomes.
136. Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML.
137. Bronchoscopic Evaluation of Pulmonary Complications in Patients Undergoing Reduced-Intensity Versus Full-Intensity Transplants.
138. T/B and not T/B: High frequency of B-cell dyscrasias in T-LGL leukemia
139. Long-Term Outcome of Cyclosporin A Therapy for T-Cell Large Granular Lymphocyte Leukemia.
140. Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins
141. Isochromosome 1q in a myelodysplastic syndrome after treatment for acute promyelocytic leukemia
142. Rare Leukemias
143. The mTOR Inhibitor Rapamycin Inhibits Drug Transport in Multidrug Resistant Cell Lines and in Acute Myeloid Leukemia (AML) Cells.
144. Natural History of Untreated Primary Hepatocellular Carcinoma
145. Long-term safety and efficacy of cyclosporin A therapy for T-cell large granular lymphocyte leukemia.
146. Pneumocystis JiroveciiInfection in Autologous Hematopoietic Stem Cell Transplant Recipients
147. Type-1 Interferon to Prevent Leukemia Relapse after Allogeneic Transplantation
148. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD.
149. A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.
150. Assessment of Individual versus Composite Endpoints of Acute Graft-versus-Host Disease in Determining Long-Term Survival after Allogeneic Transplantation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.